Press release
Hepatocellular Carcinoma Drugs Market 2024 Technology Scouting, Industry Insights, Business Outlook And Key Players Analysis Till 2033
Hepatocellular Carcinoma Drugs Market Growth
According to The Business Research Company's, The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives..
The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access.. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives..
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report
Market Drivers and Trends:
The rise in the occurrence of hepatocellular carcinoma is expected to propel the growth of the hepatocellular carcinoma drug market over the coming years. Hepatocellular carcinoma (HCC) is a primary malignant disease of the liver and the most common form of liver cancer. Hepatocellular carcinoma starts with the main type of liver cells called hepatocyte cells. Most cases of HCC result from infection with hepatitis B or C, or cirrhosis. As the occurrence of hepatocellular carcinoma continuing to rise, it leads to an increased demand for effective hepatocellular carcinoma drugs to treat the disease. For instance, in 2023, according to the report published by the American Cancer Society, Inc, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the rise in the occurrence of hepatocellular carcinoma is driving the growth of the hepatocellular carcinoma drug market.
Major companies operating in the hepatocellular carcinoma drugs market are developing laboratory-produced molecule such as monoclonal antibodies (mAb) to meet larger customer bases, more sales, and increase revenue. A monoclonal antibody (mAb) is a laboratory-produced molecule that is engineered to mimic the immune system's ability to fight off harmful pathogens such as bacteria or viruses. For instance, in October 2022, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) Indicated for adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a distinctive human monoclonal antibody that effectively binds to the PD-L1 protein. By doing so, it hinders the interaction between PD-L1 and the PD-1 and CD80 proteins. This action disrupts the tumor's evasion of the immune system, releasing the inhibition of immune responses. As for Imjudo (tremelimumab), it stands out as a human monoclonal antibody designed to specifically target the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo works by blocking CTLA-4 activity, thereby promoting T-cell activation, priming the immune response against cancer, and fostering the death of cancer cells.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp
Major Key Players of the Market:
AbbVie Inc.; Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Eisai Co.Ltd.; Eli Lilly and Company; Johnson & Johnson; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd; Gilead Sciences Inc.; GlaxoSmithKline; Exelixis Inc.; Ipsen Pharma Biotech SAS; AstraZeneca plc; BeiGene Ltd.; Ono Pharmaceutical Co. Ltd.; Roche Holdings AG; Sanofi S.A.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Otsuka Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; TTY Biopharm Company Limited; Hengrui Medicine Co. Ltd.; CSPC Pharmaceutical Group Limited; Hutchison China MediTech Limited; Jiangsu Hengrui Medicine Co. Ltd.
Hepatocellular Carcinoma Drugs Market 2024 Key Insights:
• The hepatocellular carcinoma drugs market will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%.
• Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market
• Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market
• North America was the largest region in the hepatocellular carcinoma drug market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=10809&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatocellular Carcinoma Drugs Market 2024 Technology Scouting, Industry Insights, Business Outlook And Key Players Analysis Till 2033 here
News-ID: 3752764 • Views: …
More Releases from The Business Research Company
Rail Transit Protective Coating Market Overview: Major Segments, Strategic Devel …
The rail transit protective coating sector is positioned for significant expansion in the coming years, driven by technological advancements and increasing infrastructure investments. This market is evolving rapidly as stakeholders prioritize durability, sustainability, and efficiency in rail transit systems. Let's explore the market's valuation projections, leading companies, emerging trends, and detailed segment analysis to get a clearer understanding of its future trajectory.
Expected Market Size and Growth Outlook for Rail Transit…
Analysis of Segments and Major Growth Areas in the Product Implementation Servic …
The product implementation services sector is on the verge of significant expansion, driven by evolving technology needs and increasing enterprise adoption of sophisticated systems. Understanding the current market size, key contributors, emerging trends, and segment breakdowns offers valuable insights into what lies ahead for this dynamic industry.
Market Size and Expected Growth Trajectory in the Product Implementation Services Market
The product implementation services market is projected to experience strong growth…
Key Strategic Developments and Emerging Changes Shaping the Polyvinylidene Fluor …
The polyvinylidene fluoride (PVDF) resin market is on track for significant expansion over the coming years. Driven by various technological advances and rising demands across multiple industries, this sector is expected to evolve rapidly. Let's explore the anticipated market growth, influential players, key trends, and detailed segmentation shaping the future of PVDF resin.
Projected Growth and Market Size of the Polyvinylidene Fluoride Resin Market
The PVDF resin market is forecasted…
Leading Companies Fueling Innovation and Growth in the Partyline Intercom System …
The partyline intercom systems market is gearing up for significant expansion as communication needs evolve across various industries. With increasing demand for more versatile and efficient communication tools, this sector is set to witness rapid advancements and growing adoption over the coming years. Let's explore the market size projections, key drivers, major players, emerging trends, and important segments shaping this dynamic industry.
Projected Market Size and Growth Trajectory of the Partyline…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatocellular…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
